Iraq Bulletin

Category : ACCESS Newswire

ACCESS Newswire

Fernstudium Infomaterial Unveils 2023’s Top Distance Learning Institutions in Germany

iraqbulletin.co
Bridging Distances in Education: Fernstudium Infomaterial Unveils Comprehensive Analysis of Germany’s Top Distance Learning Providers for 2023 WOLFSBURG, GERMANY / ACCESSWIRE / August 17, 2023 / Fernstudium Infomaterial, a leading online platform dedicated to providing comprehensive information about distance learning, has released its latest comparison of the top distance learning......
ACCESS Newswire

HFR, Inc. Signs Agreement With KT to Collaborate on Private 5G Business

iraqbulletin.co
SEOUL, SOUTH KOREA / ACCESSWIRE / August 7, 2023 / HFR, Inc. (KOSDAQ 230240), the leading ICT solutions provider in Korea, today announced that it will collaborate with KT Corporation (KRX:030200; NYSE:KT), Korea’s largest telecommunications service provider, to advance technology development, expand private 5G (P5G) use cases, and support digital......
ACCESS Newswire

Armor Acquires Quantum Security, Further Strengthening Its Position in the Cloud Security and IT Risk Market

iraqbulletin.co
This strategic acquisition greatly enhances Armor’s capabilities in cloud security and IT risk, delivering advanced solutions to its customers across US, EMEA, and Asia Pacific. DALLAS, TX / ACCESSWIRE / August 3, 2023 / Armor, a leading cybersecurity company providing cloud and hybrid cloud security solutions to businesses globally, today......
ACCESS Newswire

iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology

iraqbulletin.co
iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance’s development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. MIAMI, FL & VILNIUS, LITHUANIA / ACCESSWIRE / August 1,......
ACCESS Newswire

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

iraqbulletin.co
OMO-103 in Phase 1b clinical trial BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination......